Zepbound has one manufacturer, one molecule, and roughly a dozen different prices. Which one you pay is decided by three things that have nothing to do with the medicine: which of the three formats your prescription is written for, whether you buy from Lilly or from a pharmacy, and whether a calendar reminder goes off in time.
This guide prices the brand as a cash payer actually encounters it in September 2026, and it covers a route that did not exist a year ago: a federal Medicare demonstration that puts the Zepbound KwikPen at a flat $50 a month for people who qualify. Every figure below was verified on Lilly’s, CMS’s, Medicare.gov’s, the White House’s, and SingleCare’s own pages on September 4, 2026. If you want the wider view across both tirzepatide brands, our tirzepatide cost guide is the molecule-level page.
What Does Zepbound Cost Without Insurance?
The honest spread for a cash payer is $299 to about $1,086 a month, and the entire gap is channel and paperwork.
| Route | Low | Average | High |
|---|---|---|---|
| Commercial savings card, plan covers Zepbound (single-dose pen) | $25/mo | $25/mo | $25/mo |
| Medicare GLP-1 Bridge copay (KwikPen only) | $50/mo | $50/mo | $50/mo |
| Lilly self-pay, Journey Program (KwikPen or vial) | $299/mo | $449/mo | $449/mo |
| Commercial savings card, plan excludes Zepbound (KwikPen) | $299/mo | $449/mo | $449/mo |
| Lilly regular self-pay price, 45-day window missed | $299/mo | $499/mo | $699/mo |
| Commercial savings card, plan excludes Zepbound (single-dose pen) | $499/mo | $499/mo | $499/mo |
| Retail pharmacy with a discount card (2.5 mg KwikPen) | $490/mo | $509/mo | $529/mo |
| Retail pharmacy, no card and no program | $655/mo | $1,052/mo | $1,086/mo |
The Lilly rows come from Lilly’s own consumer and prescriber coverage pages. The Medicare row comes from Medicare.gov and CMS. The retail card row is SingleCare’s live Zepbound page. The top of the retail row is the list price the White House cited in its November 6, 2025 announcement, corroborated by CMS acquisition data described below.
The Lilly self-pay ladder, dose by dose
Lilly’s self-pay price applies to the single-patient-use KwikPen and the single-dose vial, and it is the same for both formats. As of September 2026 it runs $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5 mg, 10 mg, 12.5 mg, and 15 mg. A month is defined as 28 days.
That $449 is conditional. Lilly’s prescriber page states you must complete your refill purchase within 45 days of the previous delivery date to keep it. Outside that window the regular ladder applies, and Lilly currently publishes that as $299, $399, $499, $699, $699, and $699 across the six doses.
One note on vintage, because Lilly’s own documents disagree across time. The December 1, 2025 news release announcing the vial price cut footnoted a steeper regular ladder: $599 at 7.5 mg, $699 at 10 mg, $849 at 12.5 mg, and $1,049 at 15 mg. Nine months later the live pages flatten that to $499 and $699. The current pages govern, but if you see $849 or $1,049 quoted anywhere, that is the December 2025 figure, not today’s.
For the format-specific detail, see our dedicated pages on Zepbound vials and the Zepbound KwikPen.
What the pharmacy actually pays
CMS publishes the National Average Drug Acquisition Cost, which is what retail pharmacies really pay wholesalers, and Zepbound has current rows. On the August 19, 2026 effective date, the single-patient-use KwikPen prices out at about $482 a month at 2.5 mg, 5 mg, and 7.5 mg, and about $672 to $678 a month at 10 mg, 12.5 mg, and 15 mg.
The single-dose pen is a different animal entirely: four pens run roughly $1,051 to $1,052 a month at every strength. That is the presentation behind the $1,086 list price, and it is why the same drug can be quoted at $449 and at $1,086 in the same week.
Two things follow. First, Lilly’s $449 self-pay price on the 10 mg and up KwikPen is genuinely below what a pharmacy pays for that same product. Second, NADAC has no rows at all for the single-dose vial, so there is no independent acquisition benchmark for the vial presentation.
The retail counter
SingleCare’s Zepbound page, read twice on September 4, 2026, shows an average retail price of $655.33 for one 2.4 mL KwikPen at 2.5 mg/0.6 mL, and a card price as low as $490.02 for the same item. Its per-pharmacy rows on that read clustered between $490.02 and $528.94.
Treat named-pharmacy rows on any discount site as illustrative rather than fixed. Those tables move between sessions and between locations, and SingleCare’s own blog pages quote different Zepbound numbers than its price page does. The stable, twice-confirmed figures are the average retail price and the “as low as” card price.
What Drives the Price
The format on the label. Three presentations exist: the single-dose vial, the single-patient-use KwikPen, and the single-dose pen. Vial and KwikPen share the $299 to $449 self-pay ladder. The single-dose pen is the list-price product at roughly $1,086 a month. If your prescription is written for the wrong one, you are shopping in a different price universe.
Dose, but only up to a point. The self-pay price stops climbing at $449, so cost per milligram falls hard as you titrate. Ten milligrams a month at 2.5 mg costs about $29.90 per mg. Sixty milligrams a month at 15 mg costs about $7.48 per mg. On the regular ladder the climb continues to $699, so the same titration decision costs more.
Refill timing. Missing the 45-day refill window on 7.5 mg and above moves you from $449 to $499 or $699. That is up to a $250 monthly swing produced entirely by a calendar.
Insurance status, in both directions. Commercial coverage for Zepbound gets you to $25. Commercial insurance that excludes Zepbound still gets you a card. Government coverage disqualifies you from every manufacturer card there is, which is covered in detail on our Zepbound savings card page.
Pen needles and syringes. Lilly states plainly that pen needles are required and sold separately, and vials need a syringe. Budget a few dollars a month on top of every price in this guide.
Cash Price vs. Insurance
Zepbound is one of the drugs where “just use insurance” is not automatically the right answer.
If your commercial plan covers Zepbound, use it. The savings card takes the single-dose pen to as little as $25 a month, and nothing beats that. If your plan excludes weight-management drugs, which many still do, the cash ladder is not a fallback, it is your actual price, and at $299 to $449 it is competitive with a lot of specialty-tier coinsurance.
On a high-deductible plan, run the math before you fill. A pre-deductible claim on a roughly $1,086 list-price product can easily cost more than Lilly’s $449 self-pay price. The trade-off is that self-pay dollars do not count toward your deductible or your out-of-pocket maximum. Our fair price checker helps with the surrounding costs, like the visit needed to get the prescription written.
Medicare, Medicaid and the Sleep Apnea Question
This is the part that changed in 2026, and it is worth reading carefully.
Medicare Part D has long excluded drugs used for weight loss. On July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a demonstration running through December 31, 2027 that gives eligible Part D beneficiaries certain GLP-1 drugs for a flat $50 a month. Zepbound is included, but only the KwikPen. CMS states directly that the single-dose vial and single-dose pen are not available through the program. Wegovy and Foundayo are also included, so this is a multi-manufacturer Medicare model rather than a Lilly offer.
Eligibility is clinical and narrow. You must be 18 or older with a BMI of 35 or higher, or a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled hypertension, or stage 3a or higher chronic kidney disease, or a BMI of 27 or higher with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease. A prescriber must submit a prior authorization, which then stays valid through December 31, 2027 unless you switch GLP-1s.
Now the sleep apnea question, because it produces a counterintuitive answer. Zepbound’s obstructive sleep apnea indication does change Medicare coverage, but it moves you out of the Bridge rather than into it. CMS states that Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity is coverable under the basic Part D benefit, and that beneficiaries with a type 2 diabetes, moderate-to-severe OSA, or MASH-with-fibrosis diagnosis are therefore ineligible for the Bridge even if they meet every other criterion. Your cost then comes from your plan’s formulary tier and utilization management, not from a national $50 figure.
Two more cost-planning details from CMS. The $50 copay does not count toward your true out-of-pocket costs under Part D, and low-income cost-sharing subsidies do not apply to it. And coupons and discount programs cannot be applied to Bridge claims at all.
Medicaid enrollees are in the same position on manufacturer help: every Lilly Zepbound card excludes anyone enrolled in a state, federal, or government-funded healthcare program.
How to Pay Less
-
Buy the KwikPen or vial from Lilly, not the single-dose pen at a counter. That single decision is worth roughly $600 a month at the top of the range. Our cheapest way to get Zepbound guide walks the full decision tree.
-
Set a 45-day refill alarm. On 7.5 mg and above it is worth up to $250 a month, and it is the single cheapest habit on this page.
-
Check the Medicare GLP-1 Bridge before assuming Medicare pays nothing. Medicare.gov has an eligibility questionnaire, and the answer for a qualifying beneficiary is $50 a month.
-
If you have commercial insurance that excludes Zepbound, still get the card. The exclusion does not disqualify you, and the KwikPen ladder under the card matches the self-pay ladder.
-
Compare discount cards honestly, and do not expect a win here. SingleCare’s best Zepbound price is around $490 on the starting dose, which is above Lilly’s $299. Our GoodRx vs. SingleCare comparison explains where cards do and do not beat manufacturer pricing.
-
Handle the prescribing visit separately. Zepbound requires an ongoing prescriber relationship. A free or sliding-scale clinic can cover that visit cheaply, and it keeps the drug cost from being inflated by a telehealth subscription fee.
Bottom Line
In September 2026, a cash payer’s real Zepbound price is $299 to $449 a month from Lilly, $490 to $529 at a pharmacy with a discount card, and $655 to about $1,086 with nothing at all. Commercial coverage takes it to $25, and a qualifying Medicare Part D beneficiary can reach $50 through a federal program that expires December 31, 2027.
If you are still choosing between brands, our comparisons of Zepbound vs. Wegovy and Zepbound vs. Mounjaro put the self-pay ladders side by side, and the GLP-1 cost guide covers the whole class.